comparemela.com

Latest Breaking News On - லெயிஸீக் தலையீடு நிச்சயமாக - Page 1 : comparemela.com

Avinger, Inc : Avinger Tigereye CTO Crossing Featured in Live Case at LINC 2021

Avinger, Inc.: Avinger Tigereye CTO Crossing Featured in Live Case at LINC 2021 REDWOOD CITY, CA / ACCESSWIRE / February 3, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that its Tigereye CTO crossing system and Pantheris atherectomy system were featured in a live case transmission on January 29 at the Leipzig Interventional Course (LINC) 2021. LINC is a leading global forum for new methods and technology in the field of vascular medicine held each year in Leipzig, Germany. Dr. Arne Schwindt, a vascular surgeon at St. Franziskus Hospital in Münster, Germany and a pioneer in the OCT-guided treatment of vascular disease, performed the live endovascular procedure using Tigereye during a session entitled, CTO-Crossing with New OCT-Image Guided and Steerable Catheter. The patient, a 57-year-old m

Avinger Tigereye CTO Crossing Featured in Live Case at LINC 2021

Press release content from Accesswire. The AP news staff was not involved in its creation. Avinger Tigereye CTO Crossing Featured in Live Case at LINC 2021 February 3, 2021 GMT REDWOOD CITY, CA / ACCESSWIRE / February 3, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that its Tigereye™ CTO crossing system and Pantheris atherectomy system were featured in a live case transmission on January 29 at the Leipzig Interventional Course (LINC) 2021. LINC is a leading global forum for new methods and technology in the field of vascular medicine held each year in Leipzig, Germany.

Cases Presented With Fluidx GPX Embolic Device to Treat Arterial and Venous Tumor

Cases Presented With Fluidx GPX Embolic Device to Treat Arterial and Venous Tumor Created with Sketch. February 2, 2021 Fluidx Medical Technology announced that the first patient-use cases with the company’s GPX embolic device were presented by Andrew Holden, MD, at LINC 2021, the Leipzig Interventional Course held January 25-29. According to the company, the GPX embolic device is designed to combine the benefits of other embolics such as coils, particles, and liquids with simplified preparation, delivery, precision, and control leading to durable, long-term occlusions. The GPX technology is a low-viscosity, aqueous-based solution in a syringe that solidifies into a durable embolic material on delivery, without polymerization or dimethyl-sulfoxide precipitation associated with other embolics. The GPX embolic device is not available for sale in the United States or other markets and is for investigational use only, advised the company.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.